Steering Group Meeting – February 2019, London, UK

The Project HERCULES Steering Group is the decision-making body which oversees the delivery of the objectives of Project HERCULES. The group meets twice a year and is chaired by Fleur Chandler.

Access to Project HERCULES Steering Group content is restricted to Steering Group members only.

Project HERCULES team

Members include:

  • Fleur Chandler (Chair), Duchenne UK and Sanofi UK
  • Emily Reuben, Duchenne UK
  • Josie Godfrey, JG Zebra Consulting


Members include representatives from:

  • Astellas Pharma Inc
  • Catabasis Pharmaceuticals Inc
  • Pfizer Inc
  • PTC Therapeutics International Limited,
  • Roche
  • Sarepta Therapeutics Inc
  • Solid Biosciences LLC
  • Santhera Pharmaceuticals Holding AG
  • Wave Life Sciences USA

Patient groups

Members include representatives from:

  • PPMD (US)
  • World Duchenne Organisation (UPPMD)
  • Save Our Sons (Australia)
  • Stand For Duchenne Canada
  • Jesse’s Journey (Canada)


  • Prof Ron Akehurst, BresMed
  • Meriem Bouslouk, Independent German HTA expert
  • Merce Obach Cortadellas, Catsalut
  • Prof Jalpa Doshi, University of Pennsylvania
  • Karen Facey, University of Edinburgh
  • Dr Michela Guglieri, Newcastle University
  • Anthony Hatswell, Delta Hat
  • Jane Larkindale, C-Path (US)
  • Dr Anna Sarkozy, GOSH London
  • Juliana Setyawan, US
  • James Signorovitch and Susan Ward, cTAP (US)  
  • Ian Watson, NICE  
  • Dr Jarod Wong, University of Glasgow


Vendors also attend the Steering Group:

  • Aparito
  • HCD Economics
  • Oxford University Innovation
  • Pharmatelligence
  • Sheffield School of Health and Related Research (ScHARR)
  • Source HEOR
  • Tolley Health Economics
  • University of Leicester